Browse > Article
http://dx.doi.org/10.15324/kjcls.2021.53.3.257

Development of COVID-19 Neutralizing Antibody (NAb) Detection Kits Using the S1 RBD Protein of SARS-CoV-2  

Choi, Dong Ok (Department of Chemical Engineering & Biotechnology, Korea Polytechnic University)
Lee, Kang Moon (Department of Chemical Engineering & Biotechnology, Korea Polytechnic University)
Publication Information
Korean Journal of Clinical Laboratory Science / v.53, no.3, 2021 , pp. 257-265 More about this Journal
Abstract
The COVID-19 virus is a β-genus virus that causes infection by mediating the angiotensin convertible enzyme 2 (ACE2) receptor, which is distributed in large numbers in the human respiratory tract. The disease requires effective post-management of antibody production by complete healers and vaccinators because there is no perfect remedy for the virus infection. This study aimed to develop recombinant proteins specifically responsive to neutralizing antibodies in clinical specimens and use them to develop a rapid diagnostic kit to diagnose neutralizing antibodies quickly and conveniently against the COVID-19 virus and confirm the possibility of commercialization through a performance evaluation. Rapid diagnostic kits using COVID-19 S1 RBD recombinant proteins can be applied to rapid diagnostic kits, with positive percentage agreement (PPA) and negative percentage agreement (NPA) of 100% and 98.3%, respectively, compared to the U.S. FDA-approved ELISA kits. If the performance of the rapid diagnostic kit is improved and neutralizing antibodies can be analyzed quantitatively using quantitative analysis equipment, it can be used as important data to predict immunity to the COVID-19 virus and determine additional vaccinations.
Keywords
COVID-19; Immunoassay; Neutralizing antibody; Point-of-care diagnostic testing; SARS-CoV-2;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383:2603-2615. https://doi.org/10.1056/NEJMoa2034577   DOI
2 Torjesen I. Covid-19 vaccine shortages: what is the cause and what are the implications? BMJ. 2021;372:n781. https://doi.org/10.1136/bmj.n781   DOI
3 Micocci M, Gordon AL, Allen AJ, Hicks T, Kierkegaard P, McLister A, et al. COVID-19 testing in english care homes and implications for staff and residents. Age Ageing. 2021;50:668-672. https://doi.org/10.1093/ageing/afab015   DOI
4 Shajahan A, Supekar NT, Gleinich AS, Azadi P. Deducing the N-and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. Glycobiology. 2020;30:981-988. https://doi.org/10.1093/glycob/cwaa042   DOI
5 Connors M, Graham BS, Lane HC, Fauci AS. SARS-CoV-2 vaccines: much accomplished, much to learn. Ann Intern Med. 2021;174:687-690. https://doi.org/10.7326/M21-0111   DOI
6 Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382:1177-1179. https://doi.org/10.1056/NEJMc2001737   DOI
7 Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41:1141-1149. https://doi.org/10.1038/s41401-020-0485-4   DOI
8 Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol. 2020;251:228-248. https://doi.org/10.1002/path.5471   DOI
9 Chung YH, Beiss V, Fiering SN, Steinmetz NF. COVID-19 vaccine frontrunners and their nanotechnology design. ACS Nano. 2020;14:12522-12537. https://doi.org/10.1021/acsnano.0c07197   DOI
10 Morens DM, Folkers GK. What is a pandemic? J Infect Dis. 2009;200:1018-1021. https://doi.org/10.1086/644537   DOI
11 Custers J, Kim D, Leyssen M, Gurwith M, Tomaka F, Robertson J, et al. Vaccines based on replication incompetent Ad26 viral vectors: standardized template with key considerations for a risk/benefit assessment. Vaccine. 2021;39:3081-3101. https://doi.org/10.1016/j.vaccine.2020.09.018   DOI
12 Boopathi S, Poma AB, Kolandaivel P. Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. J Biomol Struct Dyn. 2021;39:3409-3418. https://doi.org/10.1080/07391102.2020.1758788   DOI
13 Speiser DE, Bachmann MF. COVID-19: Mechanisms of vaccination and immunity. Vaccines (Basel). 2020;8:404. https://doi.org/10.3390/vaccines8030404   DOI
14 Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab. 2020;318: E736-741. https://doi.org/10.1152/ajpendo.00124.2020   DOI
15 King RG, Silva-Sanchez A, Peel JN, Botta D, Meza-Perez S, Allie R, et al. Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 in mice. bioRxiv [Preprint]. 2020;11:2020.10.10.331348. https://doi.org/10.1101/2020.10.10.331348   DOI
16 World Health Organization (WHO). WHO COVID-19 Dashboard [Internet]. Geneva: World Health Organization; 2020. [cited 2021 March 17]. Available from: https://covid19.who.int/
17 Muruato AE, Fontes-Garfias CR, Ren P, Garcia-Blanco MA, Menachery VD, Xie X, et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat Commun. 2020;11:4059. https://doi.org/10.1038/s41467-020-17892-0   DOI
18 Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514-523. https://doi.org/10.1016/S0140-6736(20)30154-9   DOI
19 Bosch BJ, van der Zee R, de Haan CA, Rottier PJ. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003;77:8801-8811. https://doi.org/10.1128/jvi.77.16.8801-8811.2003   DOI
20 Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20:533-534. https://doi.org/10.1016/S1473-3099(20)30120-1   DOI
21 Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. Transmission of SARS-CoV-2: a review of viral, host, and environmental factors. Ann Intern Med. 2021;174:69-79. https://doi.org/10.7326/M20-5008   DOI
22 Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in brazil, south africa, and the UK. Lancet. 2021;397:99-111. https://doi.org/10.1016/S0140-6736(20)32661-1   DOI
23 Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5:536-544 https://doi.org/10.1038/s41564-020-0695-z   DOI